PENWEST PHARMACEUTICALS

Creation of this public company through its spin-off from a larger public company (Penford Products) that was primarily engaged in microcrystalline cellulose products for the paper industry. Penwest is a leader in time release technology for pharmaceutical products.

ICAGEN, INC.

The first institutional financing for Icagen, a drug discovery and development company, focused on ion channels. The $6 million financing was oversubscribed. Icagen recently went public on NASDAQ.

EMERGEN, INC.

$15 million equity financing for EmerGen, a population-based genomics company using the Mormon population. The Company’s focus was on reproductive biology and its strategy was to develop diagnostics and therapeutics.

KIMBERLY-CLARK HEALTHCARE

Advisory assignment to Kimberly-Clark Healthcare to assist its venture capital group, Kimberly-Clark Ventures in developing a venture capital investment program. Kimberly-Clark Ventures has made five investments to date and has acquired a product line from one of those investments.

Medical Technology / Devices

NEXRAY, INC.

A $15 million private placement of equity to finance NexRay which has developed a revolutionary, ultra low radiation dose fluoroscopy system for the cardiac catheterization lab. The financing was challenging since the Company was a restart with no revenue. It was developing expensive capital equipment to be sold into a mature market dominated by GE Medical Systems, Siemens and Phillips. Due to investor demand, the financing was increased to $21 million and was oversubscribed.

CARDIOFOCUS, INC.

$10 million private placement of equity for CardioFocus that has been developing treatments for atrial fibrillation using a novel laser technology. The Company, formerly known as Rare Earth Medical, was a restart. This first institutional financing for the Company was oversubscribed.

ACHIEVEMENT AND GUIDANCE CENTERS OF AMERICA

Sale of Achievement and Guidance Centers of America (AGCA), a psychiatric and substance abuse managed care company to American Biodyne, a private company, which subsequently merged with Medco and then Merck.

INPHYNET

Several assignments for this physician practice management company for several years. Assignments included arranging debt financing, acquisitions of two complementary companies, assisting in its initial public offering and a follow-on offering and ultimately representing the company in its merger with Med Partners.